Blueprint Medicines Comprehensive Income 2014-2024 | BPMC

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Blueprint Medicines comprehensive income for 2023 was $-0.003B, a 66.53% decline from 2022.
Blueprint Medicines comprehensive income for 2022 was $-0.01B, a 152.67% increase from 2021.
Blueprint Medicines comprehensive income for 2021 was $-0.004B, a 20.73% decline from 2020.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Blueprint Medicines comprehensive income for 2023 was $-0.003B, a 66.53% decline from 2022.
Blueprint Medicines comprehensive income for 2022 was $-0.01B, a 152.67% increase from 2021.
Blueprint Medicines comprehensive income for 2021 was $-0.004B, a 20.73% decline from 2020.

Related Stocks
Company Name	Market Cap
Amgen (AMGN)	$173B
Vertex Pharmaceuticals (VRTX)	$129.2B
Bristol Myers Squibb (BMY)	$121.3B
Gilead Sciences (GILD)	$120.8B
CSL (CSLLY)	$91.5B
Regeneron Pharmaceuticals (REGN)	$90.7B
GSK (GSK)	$75.3B
Alnylam Pharmaceuticals (ALNY)	$36.1B
Argenex SE (ARGX)	$35.2B
BioNTech SE (BNTX)	$26.1B
Biogen (BIIB)	$25.1B
Illumina (ILMN)	$24B
BeiGene (BGNE)	$20B
Moderna (MRNA)	$16.5B
Incyte (INCY)	$15.7B
Genmab (GMAB)	$15.4B
Vaxcyte (PCVX)	$12.9B
Insmed (INSM)	$12.8B
BioMarin Pharmaceutical (BMRN)	$12.6B
Bio-Techne Corp (TECH)	$11.9B
Sarepta Therapeutics (SRPT)	$11.3B
Exelixis (EXEL)	$10.3B
Revolution Medicines (RVMD)	$10.2B
QIAGEN (QGEN)	$10.1B
Intra-Cellular Therapies (ITCI)	$9.7B
Exact Sciences (EXAS)	$9.5B
Bio-Rad Laboratories (BIO.B)	$9.4B
Roivant Sciences (ROIV)	$8.7B
Repligen (RGEN)	$7.8B
Ascendis Pharma (ASND)	$7.8B